FDA briefing documents offered measured support for Moderna's mRNA-1010 flu vaccine ahead of Thursday adcomm, flagging B/Victoria strain gap but calling reactogenicity

Ahead of a Thursday advisory panel meeting, agency scientists highlighted shortcomings in data accrued for a vaccine the FDA controversially refused to even review earlier this…

Moderna's novel vaccine was at the center of dustup with agency earlier this year

U.S. health advisers are debating a new kind of flu vaccine